
WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices.
The Comera team was joined by state and local officials and members of the biotech industry, including Massachusetts State Senator Cindy F. Friedman, Massachusetts State Representative Richard M. Haggerty, Woburn Mayor Scott Galvin and Massachusetts Biotechnology Council (MassBio) President and COO Kendalle Burlin O’Connell. Comera currently has 12 employees. The increased footprint will allow the company to double its workforce in the coming years.
“The expansion of our headquarters in Woburn is a milestone achievement as we continue to advance our internal pipeline and collaborations with some of the largest biopharmaceutical companies,” said Jeffrey Hackman, Chairman and CEO of Comera. “This expansion is another step forward in supporting our continued growth as we execute on our long-term strategy to transform the lives of patients.”
Comera is developing a portfolio of proprietary injectable therapeutics – called subcutaneous (SQ) therapeutics – with the goal of making it possible for patients to administer medications that historically have been administered only by intravenous (IV) infusion. The company applies its team’s deep knowledge of formulation science and technology to transform essential biologic medicines from IV to SQ forms, which has the potential to spare patients long trips to a hospital or infusion center, where they may stay for hours to receive treatment.
“Access to necessary and lifesaving medications is a huge barrier for many in our commonwealth,” said Friedman, Senate Chair of the Joint Committee on Health Care Financing. “The work of Comera Life Sciences seeks to directly address this barrier by providing a more convenient and equitable way to access these medications. I am pleased to have Comera continue this important work in Woburn and Massachusetts.”
“I am thrilled to see Comera expanding its footprint here and continuing to develop biologic medicines in our city,” said Haggerty. “Life science firms see the benefits of locating and growing in Woburn, and I look forward to seeing what the future holds for Comera as the firm grows and increases its workforce in our community.”
“As the life sciences industry in Massachusetts continues to regionalize to places outside of Boston and Cambridge like Woburn, it makes careers available to new pools of talent and brings economic development to new cities and towns that are BioReady,” said Burlin O’Connell. “I am pleased to celebrate with our MassBio member Comera as they reach this milestone in their growth and continue to seek to deliver comfort and accessibility to patients.”
The expansion is the latest milestone achieved by Comera this year. The company made its debut as a publicly traded company on the Nasdaq index in May.
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.
To learn more about the Comera Life Sciences, visit comeralifesciences.com.